Company: GEHC
Filing Date: 2025-12-02
Form Type: 424B2
Source: 0001193125-25-305442
Chunk: 16

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-12-02
Form: 424B2
Chunk 16
---

notes bearing interest at fixed rates of interest and market interest rates increase, the market values of those notes may decline. We cannot predict the future level of market interest rates.

S-8

USE OF PROCEEDS

We estimate that the net proceeds from this offering will be approximately $1,235.6 million, after deducting underwriting discounts and
commissions and estimated offering expenses payable by us.

We intend to use the net proceeds from this offering, together with borrowings
under our New Term Loan Facility and cash on hand (and borrowings under the Bridge Facility, if needed), to pay all or a portion of the purchase price of the Acquisition, to pay associated costs and expenses, and for other general corporate
purposes, which may include repayment of short-term indebtedness.

S-9

CAPITALIZATION The following table sets forth our consolidated cash, cash equivalents and restricted cash and our capitalization, in each case as of September 30, 2025, (i) on an actual basis, and (ii) as adjusted to give effect to (x) this offering, (y) additional borrowings of $750 million we expect to incur under our New Term Loan Facility in connection with the closing of the Acquisition and (z) the application of the net proceeds from this offering, together with the borrowings under the New Term Loan and cash on hand, to fund the purchase price for the Acquisition as described under the heading “Use of Proceeds” in this prospectus supplement. For purposes of this presentation, the net proceeds from borrowings under the New Term Loan Facility and the notes offered hereby are reflected as cash and cash equivalents in the As Adjusted column of this table. You should read this table in conjunction with “Use of Proceeds” appearing elsewhere in this prospectus supplement as well as “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our unaudited condensed consolidated financial statements and the accompanying notes, which are incorporated by reference into this prospectus supplement from our Quarterly Report on Form 10-Qfor the quarter ended September 30, 2025.

|                                                                                              |     | As of September 30, 2025 |        |   |     |                |        |   |
|:---------------------------------------------------------------------------------------------|:----|:-------------------------|-------:|:--|:----|:---------------|-------:|:--|
| ($ in millions)                                                                              |     | Actual                   |        |   |     | As Adjusted(1) |